Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506502 | 0.86 | TSHR (0.66) | CREBBPMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL16954384 | 0.86 | MAPT (0.54) | CREBBPMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6246000 | 0.85 | MAPT (0.57) | CREBBPMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL27459572 | 0.85 | MAPK1 (0.67) | CREBBPMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL10018556 | 0.84 | KMT2A (0.74) | CREBBPMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3034164 | 0.84 | CREBBP (0.72) | CREBBPMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29463757 | 0.84 | CREBBP (0.72) | CREBBPMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29888190 | 0.83 | ALDH1A1 (0.51) | CREBBPMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6601501 | 0.83 | MAPT (0.59) | CREBBPMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13952661 | 0.82 | THRA (0.59) | CREBBPMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2021-08-05 | — | — | US | disclosed |
| EP-3736270-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3736267-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-27 | — | — | US | disclosed |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-20 | — | — | US | disclosed |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| EP-3736267-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| EP-3736270-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| EP-3681864-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019053634-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2019-03-14 | — | — | US | disclosed |
| EP-1861395-B1 | 5-(1,3-DIARYL-1H-PYRAZOL-4-YLMETHYLENE)-THIAZOLIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTICANCER AGENT | KOREA RES INST CHEM TECH (KR) | 2010-12-29 | — | — | EP | disclosed |
| US-7718681-B2 | 5-(1,3-Diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine,2,4-dione derivatives useful as anticancer agent | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-05-18 | — | — | US | disclosed |
| US-20080275094-A1 | 5-(1,3-Diaryl-1H-Pyrazol-4-1 Methylene)-Thiazolidine-2,4-Dione Derivatives Useful as Anticancer Agent | BARCLAYS BANK PLC (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1861395-A1 | 5-(1,3-DIARYL-1H-PYRAZOL-4-YLMETHYLENE)-THIAZOLIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTICANCER AGENT | Korea Research Institute of Chemical Technology (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101307-A1 | 5-(1,3-DIARYL-1H-PYRAZOL-4-YLMETHYLENE)-THIAZOLIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTICANCER AGENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
| US-20080275094-A1 | 5-(1,3-Diaryl-1H-Pyrazol-4-1 Methylene)-Thiazolidine-2,4-Dione Derivatives Useful as Anticancer Agent | TP53, CDKN1A, API5 | CREBBP 1340/4885MAPT 2588/4885MEN1 1251/4885 |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CREBBP 1354/4885MAPT 4885/4885MEN1 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.